Neuro-Pain Provides a Dynamic and Interactive Register for the Invasvive Neuromodulatory Therapies for Different Chronic Pain Syndromes. Patients Living in Belgium and Suffering From Persistent Spinal Pain Syndromes Type 2 as Well as Suffering From Complex Regional Pain Syndromes Are Included.

Nationwide Dynamic Register for Screening, Evaluation and Follow-up of Patients Suffering From Chronic Pain Syndromes and Treated by Means of Invasive Neuromodulation.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06835868

Enrollment

7000

Registered

2025-02-19

Start date

2018-02-14

Completion date

2032-01-01

Last updated

2025-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain Syndromes, CRPS

Keywords

spinal cord stimulation, chronic pain, quality of life

Brief summary

Patients suffereing from chronic pain due to persistent spinal pain syndromes or complex regional pain syndromes and living in Belgium will be included in this register once they are being considered for a treatment with invasive neuromodulation (either spinal cord stimulation either dorsal root ganglion stimulation). The screening process, the multidisciplinary evaluation, the trial therapy and the long-terl follow-up will be monitored through this register.

Interventions

PROCEDURESpinal cord stimulation

implantation of electrode which is linked to an implantable impulse generator for the treatment of chronic pain syndromes.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* chronic pain syndromes

Exclusion criteria

* acute pain syndromes

Design outcomes

Primary

Measure	Time frame	Description
Pain intensity after 21 days	21 days	Follow-up of pain intensity (measured by the Numeric Rating Scale, with a minimum of 0 and a maximum score of 10) during the trial therapy of 21 days, together with quality of sleep and quality of ambulation (also ona NRS scale from 0 to 10).

Countries

Belgium

Contacts

Primary ContactGuy H HANS, MD, PhD

guy.hans@uza.be003238213000

Backup ContactLisa Bernaerts

lisa.bernaerts@uza.be00323821300

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026